Amarin Corp Plc (AMRN)

[InTheTrenches]

While it is true that VLDL (very-low-density lipoprotein) is worse than LDL, a high level of either is not good.

Further, a typical cholesterol test doesn't usually break out the VLDL and LDL. That is, a physician wouldn't even see the VLDL/LDL breakdown, and would only care if the LDL total is high or increasing.

If Anchor meets or exceeds SPA requirements and is approved, the marketing potential in dyslipidemia, based on a typical cholesterol test, will be huge.

If we exceed the SPA, there is still the issue of what the FDA is looking for in an outcomes study, but we don't have enough info on that yet.


Supporting read:

www.mayoclinic.com/health/vldl-cholesterol/AN01335